• Title/Summary/Keyword: 동시암

Search Result 504, Processing Time 0.023 seconds

Basaltic Andesite-Siltstone Peperite in the Gyehwari Formation (Cretaceous) (백악기 계화리층 내 현무암질 안산암-실트암 페퍼라이트)

  • Noh, Beyong-Seob;Park, Jae-Moon;Kim, Seung-Bum;Ryang, Woo-Hun
    • Journal of the Korean earth science society
    • /
    • v.30 no.1
    • /
    • pp.33-39
    • /
    • 2009
  • This paper presents the occurrence and characteristics of the basaltic andesite-siltstone peperite in the lower part of the Gyehwari Formation (Cretaceous), Buan-gun, Jeonbuk province, SW Korea. The peperite is associated with tabular basaltic andesite body, concordantly intercalated with red siltstone and silty sandstone interbeds of floodplain facies. Development of the peperite along the upper margin of the andesite and its textural transition from a dispersed blocky type inward into a closely packed type collectively indicate an intrusive origin (?sill) of the andesite. Magma intrusion and subsequent peperite formation suggest an active syndepositional volcanism since the early stage of evolution of the Gyehwa Basin. The andesite is dated at Late Cretaceous (Santonian) by K-Ar whole-rock radiometric method.

Postoperative Complications after Preoperative Chemoradiotherapy Combined with Hyperthermia in Locally Advanced Rectal Cancer (국소 진행성 직장암의 수술전 동시 화학방사선치료와 온열치료병합시 수술후 부작용)

  • Yea, Ji Woon
    • Progress in Medical Physics
    • /
    • v.25 no.2
    • /
    • pp.89-94
    • /
    • 2014
  • We investigated whether regional hyperthermia (HT) increased post-surgical complications in patients with locally advanced rectal cancer treated with preoperative concurrent chemoradiotherapy (CCRT). Between 1996 and 2007, 205 patients treated with preoperative CCRT and curative surgery were evaluable for the analysis of acute and late toxicities. A total dose of 39.6 Gy or 45 Gy was delivered concurrently with one or two cycles of chemotherapy (5-fluorouracil, leucovorin). Eighty-eight patients received regional HT twice a week using an 8-MHz radiofrequency capacitive heating device. Surgery was performed 4~6 weeks after the completion of preoperative CCRT. The median age was 59 years (range, 18~83) and the median follow-up period was 61months (range, 2~191). The 5-year overall survival and complication-free survival rate of all patients was 77.4% and 73.7%, respectively. Early leakage, delayed leakage, anastomotic stricture, fistula, and small bowel obstruction occurred in 1.0%, 2.9%, 1.5%, 5.9%, and 17.1%, respectively. HT did not increase all kinds of complications. The 5-year complication-free survival rate was 71.8% in the non-HT group and 76.3% in the HT group (p=0.293). Regional HT did not increase postoperative complications in patients with locally advanced rectal cancer treated with preoperative CCRT followed by curative surgery.

Hereditary Colorectal Cancer (유전성 대장암)

  • Kim, Duck-Woo
    • Journal of Genetic Medicine
    • /
    • v.7 no.1
    • /
    • pp.24-36
    • /
    • 2010
  • Colorectal cancer is one of the most steeply increasing malignancies in Korea. Among 398,824 new patients recorded by the Korea Central Cancer Registry between 2003 and 2005, 47,915 cases involved colorectal cancers, accounting for 12.0 % of all malignancies. In 2002, total number of colorectal cancer cases had accounted for 11.2 % of all malignancies. Hereditary syndromes are the source of approximately 5% to 15% of overall colorectal cancer cases. Hereditary colorectal cancers are divided into two types: hereditary nonpolyposis colorectal cancer (HNPCC), and cancers associated with hereditary colorectal polyposis, including familial adenomatous polyposis (FAP), Peutz-Jeghers syndrome, juvenile polyposis, and the recently reported hMutYH (MYH)-associated polyposis (MAP). Hereditary colorectal cancers have unique clinical features distinct from sporadic cancer because these are due to germline mutations of the causative genes; (i) early age-of-onset of cancer, (ii) frequent association with synchronous or metachronous tumors, (iii) frequent association with extracolonic manifestations. The management strategy for patients with hereditary colorectal cancer is quite different from that for sporadic cancer. Furthermore, screening, genetic counseling, and surveillance for at-risk familial member are also important. A well-organized registry can plays a central role in the surveillance and management of families affected by hereditary colorectal cancers. Here, we discuss each type of hereditary colorectal cancer, focusing on the clinical and genetic characteristics, management, genetic screening, and surveillance.

Concurrent Chemoradiotherapy in Elderly Patients with Locally Advanced Esophageal Carcinoma (고령의 국소 진행된 식도암환자에서 동시 항암화학방사선치료)

  • Jung, Bae-Kwon;Kang, Ki-Mun;Lee, Gyeong-Won;Kang, Jung-Hoon;Kim, Hoon-Gu;Lee, Won-Seob;Chai, Gyu-Young
    • Radiation Oncology Journal
    • /
    • v.27 no.2
    • /
    • pp.84-90
    • /
    • 2009
  • Purpose: The effect of concurrent chemoradiotherapy was analyzed in elderly patients when used in the treatment of locally advanced esophageal cancer. Materials and Methods: The retrospective analysis included 28 elderly patients aged 65 or older, with histopathologically confirmed squamous cell carcinoma of the esophagus, underwent concurrent chemoradiotherapy from January 2001 to July 2007. The squamous cell carcinoma disease stages included 8 patients (28.8%) in stage IIa, 10 patients (35.7%) in stage IIb, and 10 patients (35.7%) in stage III. Fractionated radiotherapy was performed with a 6 MV or 10 MV X-ray for 45~63 Gy (median: 59.4 Gy). Chemotherapy was applied concurrently with the initiation of radiotherapy. A 75 mg/$m^2$ dose of Cisplatin was intravenously administered on day 1. Further, 5-FU 1,000 mg/$m^2$ was continuously administered intravenously from days 1 to 4. This regimen was performed twice at 3-week intervals during radiotherapy. Two cycles of consolidation chemotherapy was performed after radiotherapy. Results: The follow-up period was 3~72 months (median: 19 months). The treatment responses after concurrent chemoradiotherapy included a complete response in 11 patients (39.3%), a partial response in 14 patients (50.0%), and no response in 3 patients (10.7%). The overall response rate was 89.3% (25 patients). The overall 1-, 2- and 3-year survival rates were 55.9%, 34.6% and 24.2%, respectively. The median survival time was 15 months. Two-year survival rates of patients with a complete response, partial response, and no response were 46.2%, 33.0%, and 0%, respectively. The stage and tumor response after concurrent chemoradiotherapy were statistically significant prognostic factors related with survival. No treatment-related deaths occurred in this study. Conclusion: Concurrent chemoradiotherapy is a relatively effective treatment without serious complications in elderly patients with locally-advanced esophageal cancer.

Synchronous Double Primary Cancers of Lung and Liver (폐와 간의 동시성 원발성 중복암)

  • Lim, So Yeon;Sim, Yun Su;Lee, Jin Hwa;Kim, Tae-Hun;Ryu, Yon Ju;Chun, Eun Mi;Kim, Yoo Kyung;Lee, Jung Kyong;Sung, Sun Hee;Ahn, Jae Ho;Chang, Jung Hyun
    • Tuberculosis and Respiratory Diseases
    • /
    • v.62 no.4
    • /
    • pp.318-322
    • /
    • 2007
  • Although reports of multiple primary malignant tumors have increased recently, cases of synchronous double primary tumors of lung and liver are rare. A 73-year-old man suffered from chronic cough. His chest x-ray showed segmental atelectasis of the right upper lobe. Bronchoscopy revealed a mass occluding the orifice of the anterior segmental bronchus of the right upper lobe, and a biopsy showed a squamous cell carcinoma. A synchronous hepatic mass was found by ultrasonography. However, F18-FDG-PET showed no evidence of a distant metastasis. The liver biopsy revealed a hepatocellular carcinoma. A right upper lobe lobectomy and a sleeve resection were performed for the lung cancer, and radiofrequency ablation was performed for the hepatocellular carcinoma.

Development of Vision system for Back Light Unit of Defect (백라이트 유닛의 결함 검사를 위한 비전 시스템 개발)

  • Cho, Sang-Hee;Han, Chang-Ho;Oh, Choon-Suk;Ryu, Young-Kee
    • Proceedings of the KIEE Conference
    • /
    • 2005.10b
    • /
    • pp.127-129
    • /
    • 2005
  • 본 연구에서는 백라이트 유닛의 검사를 위한 머신비전 시스템을 구축한다. 시스템은 크게 하드웨어와 소프트웨어로 나눌 수 있고 하드웨어는 조명부, 영상획득부, 로봇 암 제어부로 분류된다. 조명부는 36W FPL램프로 구성되었고 조명부의 상판에 아크릴판을 거치대로 이용하여 백라이트 유닛을 거치한다. 로봇 암 제어부는 2축 로봇 암을 제어하여 로봇 암의 센서부착 지지대에 부착된 CCD 센서를 이동시킨다. 이와 동시에 영상획득부에서는 이미지를 획득하여 PC로 전송한다. 소프트웨어의 화상처리 검사 알고리즘은 일정 패턴이 있는 도광판에 대한 검사 알고리즘과 일정패턴이 없근 백라이트 유닛에 대한 검사 알고리즘으로 분리된다. 일정 패턴이 인쇄되어 있는 패널에 대한 검사 알고리즘은 모폴로지 연산을 이용하는 템플릿 체크방법과 블록 매칭 방법이 사용되었고 일정패턴이 없는 유닛에 대한 검사는 개선된 Otsu 방법을 이용하여 얼룩이나 흐릿한 결함에 대한 결함을 검출하였다. 실험결과 불균일한 결함과 밝기가 일정하지 않은 결함일지라고 90% 이상의 검출율로 뛰어난 성능을 입증하였다.

  • PDF

A Case of Bilateral Tonsillar Cancer Discovered in Metastatic Carcinoma of Unknown Origin (원발미상의 경부 전이암에서 발견된 양측 편도암 1예)

  • Choi, Jeong-Seok;Lim, Jae-Yol;Han, Chang-Dok;Kim, Young-Mo
    • Korean Journal of Head & Neck Oncology
    • /
    • v.28 no.1
    • /
    • pp.16-18
    • /
    • 2012
  • Ipsilateral tonsillectomy and panendoscopy-guided biopsy following imaging studies are considered a standard procedure in the search for a primary origin in patients with cervical metastatic carcinoma of unknown origin(MUO). However, many authors recommended bilateral tonsillectomy for the determination of the primary site of a MUO, because cervical metastasis may occur contralateral to tonsillar carcinoma. The authors attempted to address the clinical implications of using routine bilateral tonsillectomy to determine the primary site of MUOs based on a case report of cervical MUO that was finally diagnosed as a bilateral synchronous tonsillar carcinoma with cervical metastasis after a diagnostic work-up that included bilateral tonsillectomy.

Applications of Next-Generation Sequencing Technology based on Liquid Biopsy for Solid Tumor (고형암에서 액체 생검 기반의 차세대염기서열분석법 응용 기술)

  • Kim, Jin-Hee
    • Proceedings of the Korea Contents Association Conference
    • /
    • 2019.05a
    • /
    • pp.469-470
    • /
    • 2019
  • 차세대염기서열분석법(NGS, Next Generation Sequencing) 기술은 하나의 유전체를 무수히 많은 조각으로 분해하여 각 조각을 동시에 읽어낸 뒤, 전산기술을 이용하여 조합함으로써 방대한 유전체 정보를 빠르게 해독하는 방법이다. 한편, 액체 생검(LB, liquid biopsy)이란 암세포가 깨지면서 생기는 미량의 DNA 조각을 말초혈액 속에서 찾아내 암을 진단하는 기술로 조직 생검(tissue biopsy)에 비해 비침습적이다. 본 논문은 NGS와 LB 기술을 접목했을 때 확진이 가능하고 예후 및 치료경과의 예측이 가능함을 제언하였다.

  • PDF

Retrospective Analysis of Chemoradiotherapy for Limited-Stage Small-Cell Lung Cancer (제한병기 소세포암 환자의 항암화학방사선요법에 대한 후향적 분석)

  • Lee, Jong-Hoon;Kim, Sung-Hwan;Kim, Su-Zy;Lee, Joo-Hwan;Kim, Hoon-Kyo;Shim, Byoung-Yong
    • Radiation Oncology Journal
    • /
    • v.27 no.3
    • /
    • pp.133-139
    • /
    • 2009
  • Purpose: This study was designed to analyze the outcome and toxicity of thoracic radiation therapy (TRT) and chemotherapy for patients who suffer with limited-stage small-cell lung cancer (LS-SCLC). Materials and Methods: We retrospectively studied 35 patients with LS-SCLC. TRT was administered once daily (1.8 to 2 Gy per fraction) and it was directed to the primary tumor for a total 50 to 66 Gy in 6 to 7 weeks. The patients received four cycles of etoposide plus cisplatin. TRT was begun on day 1 of the first cycle of chemotherapy in the concurrent arm and after the fourth cycle in the sequential arm. Results: The median progression-free survival time was 16.5 months (95% confidence interval [CI], 9.0 to 24.1 months) for the sequential arm, and 26.3 months (95% CI, 16.6 to 35.9 months) for the concurrent arm. The 2-year progression-free survival rate was 16.0 percent for the sequential arm and 50.0 percent for the concurrent arm (p=0.0950 by log-rank test). Leukopenia was more severe and more frequent in the concurrent arm than in the sequential arm. However, severe esophagitis was infrequent in both arms. The radiotherapy was interrupted more frequently in the concurrent arm than in the sequential arm due to hematologic toxicities (p=0.001). Conclusion: This study suggests that concurrent TRT with etoposide plus cisplatin is more effective for the treatment of LS-SCLC than sequential TRT. However, there is a significant increase in the risk of toxicities, and radiotherapy was frequently interrupted in the concurrent arm due to hematologic toxicities.

Preoperative Concurrent Radiochemotherapy for Locally Advanced Esophageal Cancer: Treatment Outcome and Prognostic Factors (국소 진행된 식도암에 대한 수술 전 동시병용 방사선-항암 화학요법: 치료 성적과 예후인자에 대한 연구)

  • Kim, Hae-Young;Kim, Kwan-Min;Kim, Jhin-Gook;Shim, Young-Mog;Im, Young-Hyuck;Ahn, Yong-Chan
    • Radiation Oncology Journal
    • /
    • v.25 no.3
    • /
    • pp.160-169
    • /
    • 2007
  • Purpose: This study reports the results of the use of preoperative concurrent radiochemotherapy (CRCT) for the treatment of locoregionally advanced esophageal cancer. Materials and Methods: From 1998 through 2005, 61 patients with intrathoracic esophageal cancer at stages II-IVB (without distant organ metastasis and presumed to be respectable) received preoperative CRCT. CRCT consisted of radiotherapy (45 Gy /25 fractions /5 weeks) and FP chemotherapy (5-FU 1 g/$m^{2}$/day, days 1-4 and 29-32, Cisplatin 60 mg/$m^{2}$/day, days 1 and 29). An esophagectomy was planned in $4{\sim}6$ weeks after the completion of CRCT. Results: There were two treatment-related deaths. Among the 61 patients, 53 patients underwent surgery and 17 patients achieved a pathological complete response (pCR). The overall survival (OS) rates of all 61 patients at 2 and 5 years were 59.0% and 38.0%, respectively. The rates of OS and disease-free survival (DFS) of the surgically resected patients at 2 and 5 years were 61.6%, 40.1 % and 53.3%, 41.8%, respectively. By univariate analysis, achieviement of pCR and a clinically uninvolved distant lymph node (cMO) were favorable prognostic factors for OS and DFS. There were 27 patients that experienced a relapse-a locoregional relapse occurred in 5 patients, a distant metastasis occurred in 12 patients and combined failure occurred in 10 patients. Conclusion: The results of the current study are favorable. pCR and an uninvolved distant lymph node were found to be favorable prognostic factors.